Minireviews
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Exp Med. Sep 20, 2025; 15(3): 106743
Published online Sep 20, 2025. doi: 10.5493/wjem.v15.i3.106743
Potential role of nanopharmacology in reducing neuroinflammation associated with hypertension and metabolic disorders
Virna Margarita Martín Giménez, Sebastián García Menéndez, Raúl Lelio Sanz, Máximo Schiavone, Leon Ferder, Felipe Inserra, Walter Manucha
Virna Margarita Martín Giménez, Instituto de Investigaciones en Ciencias Químicas, Facultad de Ciencias Químicas y Tecnológicas, Universidad Católica de Cuyo, San Juan 5400, Argentina
Sebastián García Menéndez, Department of Pharmacology, Instituto de Medicina y Biología Experimental de Cuyo, Consejo Nacional de Investigación Científica y Tecnológica, Mendoza 5500, Argentina
Raúl Lelio Sanz, Department of Pathology, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza 5500, Argentina
Máximo Schiavone, Department of Medicina, Universidad Austral, Ciudad Autónoma de Buenos Aires C1010AAZ, Argentina
Leon Ferder, Department of Pharmacology, Universidad Maimónides, Ciudad Autónoma de Buenos Aires C1405, Argentina
Felipe Inserra, Department of Nephrology, Universidad de Maimónides, Ciudad Autónoma de Buenos Aires C1405, Argentina
Walter Manucha, Department of Pathology, Instituto de Medicina y Biología Experimental de Cuyo, Consejo Nacional de Investigación Científica y Tecnológica Universidad Nacional de Cuyo, Laboratorio de Farmacología Experimental Básica y Traslacional, Facultad de Ciencias Médicas, Mendoza 5500, Argentina
Co-first authors: Virna Margarita Martín Giménez and Sebastián García Menéndez.
Author contributions: All authors contributed to the writing, discussion and preparation of this manuscript.
Supported by Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación, No. PICT 2020 Serie A 4000.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Walter Manucha, PhD, Professor, Department of Pathology, Instituto de Medicina y Biología Experimental de Cuyo, Consejo Nacional de Investigación Científica y Tecnológica Universidad Nacional de Cuyo, Laboratorio de Farmacología Experimental Básica y Traslacional, Facultad de Ciencias Médicas, Farmacología, Mendoza 5500, Argentina. wmanucha@yahoo.com.ar
Received: March 11, 2025
Revised: April 17, 2025
Accepted: May 26, 2025
Published online: September 20, 2025
Processing time: 154 Days and 20.3 Hours
Core Tip

Core Tip: This mini-review unveils the intricate nexus between hypertension, metabolic disorders, and neurodegeneration, spotlighting neuroinflammation as a pivotal mediator. Compromised cerebral blood flow and blood-brain barrier (BBB) disruption initiate a cascade of oxidative stress and pro-inflammatory cytokine release, culminating in neuronal injury. We advocate for the transformative potential of nanopharmacology. Nanoparticle-mediated drug delivery offers a strategic avenue to enhance therapeutic bioavailability and selectivity, enabling targeted intervention across the BBB. By synergizing effective blood pressure management with nanotechnology-driven modulation of neuroinflammation, we pioneer novel strategies to mitigate neurodegenerative pathologies. This paradigm shift holds promise for revolutionizing therapeutic approaches, paving the way for improved patient outcomes in hypertension-associated neurological disorders.